Entropy Neurodynamics is a high-risk, high-asymmetry psychedelic biotech betting that controllable IV psilocin can unlock scalable treatment for IBS, binge eating disorder, and chronic gut-brain conditions.
Overview
Entropy Neurodynamics is a pre-revenue Australian clinical-stage biotech developing psilocin-assisted psychotherapy for neuropsychiatric and gut-brain disorders. Its lead platform, TRP-8803, delivers IV psilocin with fast onset, precise clinician control, and on-demand termination, potentially solving the long-duration and unpredictability limitations of oral psilocybin. The company is focused on BED, IBS, fibromyalgia, and chronic pain, funded mainly by equity, R&D tax incentives, and loan facilities. The opportunity is high-risk but potentially asymmetric if clinical validation and licensing emerge.